Long-term effectiveness and tolerability of topiramate in children with epilepsy under the age of 2 Years: 4-year follow-up

Journal of Korean Medical Science

Volumn 24, Issue 6, 2009, Pages 1078-1082

  Kim, Jung Mi ^a   Kwon, Soonhak ^a   Seo, Hye Eun ^a   Choe, Byung Ho ^a   Cho, Min Hyun ^a   Park, Sung Pa ^a  

^a Kyungpook National University School of Medicine   (South Korea)

Author keywords

Adverse effects; Carbamazepine; Topiramate; Treatment outcome

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; DRUG DERIVATIVE; FRUCTOSE; TOPIRAMATE;

ARTICLE; CHILD; EPILEPSY; FEMALE; FOLLOW UP; HUMAN; INFANT; MALE; PRESCHOOL CHILD; TREATMENT OUTCOME;

ANTICONVULSANTS; CARBAMAZEPINE; CHILD; CHILD, PRESCHOOL; EPILEPSY; FEMALE; FOLLOW-UP STUDIES; FRUCTOSE; HUMANS; INFANT; MALE; TREATMENT OUTCOME;

EID: 75349108991     PISSN: 10118934     EISSN: 15986357     Source Type: Journal    
DOI: 10.3346/jkms.2009.24.6.1078     Document Type: Article

References (25)

1. Aicardi J. Risks and benefits of new antiepileptic agents in children. Rev Neurol 2000; 31: 376-81.
2. Bourgeois BF. Pharmacokinetics and pharmacodynamics of topiramate. J Child Neurol 2000; 15 (Suppl 1): S27-30.
3. Bebin M. Pediatric partial and generalized seizures. J Child Neurol 2002; 17 (Suppl 1): S65-9.
4. Blumkin L, Lerman-Sagie T, Houri T, Gilad E, Nissenkorn A, Ginsberg M, Watemberg N. Pediatric refractory partial status epilepticus responsive to topiramate. J Child Neurol 2005; 20: 239-41.
5. Bootsma HP, Aldenkamp AP, Diepman L, Hulsman J, Lambrechts D, Leenen L, Majoie M, Schellekens A, de Krom M. The effect of antiepileptic drugs on cognition: patient perceived cognitive problems of topiramate versus levetiracetam in clinical practice. Epilepsia 2006; 47 (Suppl 2): 24-7.
6. Wheless JW. Use of topiramate in childhood generalized seizure disorders. J Child Neurol 2000; 15 (Suppl 1): S7-13.
7. Waugh J, Goa KL. Topiramate: as monotherapy in newly diagnosed epilepsy. CNS Drugs 2003; 17: 985-92.
8. Markind JE. Topiramate: a new antiepileptic drug. Am J Health Syst Pharm 1998; 55: 554-62.
9. Ormrod D, McClellan K. Topiramate: a review of its use in childhood epilepsy. Paediatr Drugs 2001; 3: 293-319.
10. Nicolson A, Appleton RE, Chadwick DW, Smith DF. The relationship between treatment with valproate, lamotrigine, and topiramate and the prognosis of the idiopathic generalised epilepsies. J Neurol Neurosurg Psychiatry 2004; 75: 75-9.
11. Privitera MD, Brodie MJ, Mattson RH, Chadwick DW, Neto W, Wang S. Topiramate, carbamazepine and valproate monotherapy: double-blind comparison in newly diagnosed epilepsy. Acta Neurol Scand 2003; 107: 165-75.
12. Korinthenberg R, Schreiner A. Topiramate in children with west syndrome: a retrospective multicenter evaluation of 100 patients. J Child Neurol 2007; 22: 302-6.
13. Rosenfeld WE, Doose DR, Walker SA, Baldassarre JS, Reife RA. A study of topiramate pharmacokinetics and tolerability in children with epilepsy. Pediatr Neurol 1999; 20: 339-44.
14. Mikaeloff Y, de Saint-Martin A, Mancini J, Peudenier S, Pedespan JM, Vallee L, Motte J, Bourgeois M, Arzimanoglou A, Dulac O, Chiron C. Topiramate: efficacy and tolerability in children according to epilepsy syndromes. Epilepsy Res 2003; 53: 225-32.
15. Mikaeloff Y, Rey E, Soufflet C, d'Athis P, Echenne B, Vallee L, Bouhours P, Grinspan A, Dulac O, Pons G, Chiron C. Topiramate pharmacokinetics in children with epilepsy aged from 6 months to 4 years. Epilepsia 2004; 45: 1448-52.
16. Chung S, Wang N, Hank N. Comparative retention rates and longterm tolerability of new antiepileptic drugs. Seizure 2007; 16: 296-304.
17. Zaccara G, Messori A, Cincotta M, Burchini G. Comparison of the efficacy and tolerability of new antiepileptic drugs: what can we learn from long-term studies? Acta Neurol Scand 2006; 114: 157-68.
18. Bootsma HP, Coolen F, Aldenkamp AP, Arends J, Diepman L, Hulsman J, Lambrechts D, Leenen L, Majoie M, Schellekens A, de Krom M. Topiramate in clinical practice: long-term experience in patients with refractory epilepsy referred to a tertiary epilepsy center. Epilepsy Behav 2004; 5: 380-7.
19. Moreland EC, Griesemer DA, Holden KR. Topiramate for intractable childhood epilepsy. Seizure 1999; 8: 38-40.
20. Mohamed K, Appleton R, Rosenbloom L. Efficacy and tolerability of topiramate in childhood and adolescent epilepsy: a clinical experience. Seizure 2000; 9: 137-41.
21. Voronkova KV, Pylaeva OA, Petrukhin AS. Efficacy of topiramate (Topamax) in epileptic patients of different ages. Neurosci Behav Physiol 2007; 37: 547-51.
22. Nieto-Barrera M, Candau R, Nieto-Jimenez M, Correa A, del Portal LR. Topiramate in the treatment of severe myoclonic epilepsy in infancy. Seizure 2000; 9: 590-4.
23. Nieto-Barrera M, Nieto-Jimenez M, Candau R, Ruiz del Portal L. Anhidrosis and hyperthermia associated with treatment with topiramate. Rev Neurol 2002; 34: 114-6.
24. Mukhin K, Glukhova L, Petrukhin AS, Mironov MB, Sobornova AM. Topamax in monotherapy of epilepsy. Zh Nevrol Psikhiatr Im S S Korsakova 2004; 104: 35-40.
25. Malphrus AD, Wilfong AA. Use of the newer antiepileptic drugs in pediatric epilepsies. Curr Treat Options Neurol 2007; 9: 256-67.